von Tobias Borgers | Feb. 2, 2024 | Glaxo
When Matt Hill, PhD, was in graduate school, the human genome sequence was more or less finished and companies like 454 and Solexa were starting to make waves in next-gen sequencing (NGS). But Hill became more enamored with synthetic biology—engineering the genetic...
von Tobias Borgers | Feb. 2, 2024 | Bayer
NAIROBI (Reuters) – Germany’s Bayer will contract a third party to distribute its pharmaceutical products in four African markets including Kenya, it said, adding that the impact on jobs will be minimal. The company, which has 200 employees in the region,...
von Tobias Borgers | Jan. 19, 2024 | Boehringer
Klinische Studien, Biobank-Daten, elektronische Krankenakten, Lieferketten- und Produktionsdaten: In der Pharmabranche stehen unendlich viele Daten bereit. Sie alle haben das Potenzial, uns schneller an das Ziel zu bringen, Menschen und Tieren zu helfen. Mit ihnen...
von Tobias Borgers | Jan. 19, 2024 | Boehringer
INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals, Inc. and 3T Biosciences („3T“) today announced they have entered into a new strategic collaboration and licensing agreement focused...
von Tobias Borgers | Jan. 19, 2024 | Bayer
Sun Pharmaceutical Industries Limited and Bayer on Thursday announced that both companies have signed an agreement to market and distribute a second brand of Finerenone in India. According to the company’s press statement, Finerenone, a patented medicine is indicated...
